Corbus Pharma (NASDAQ: CRBP) announced that patient enrollment has commenced in the Phase 2 clinical study of its investigational new ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE